Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer

By sjmartinez • January 30, 2023

Davidson TM, Lebreton CL, Hendricksen AEW, Atkinson HJ, Larson MC, Oberg AL, Provencher DM, Glaspy JA, Karlan BY, Slamon DJ, Konecny GE, Ray-Coquard IL. Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol. 2023 Jan 27;170:221-228. doi: 10.1016/j.ygyno.2023.01.021. Epub ahead of print. PMID: 36709663.

Tags: AMG 479, Ganitumab, Hematology/Oncology, IGFR1 inhibitor, Insulin-like growth factor, ovarian cancer, Publications, targeted therapy

Treatment Patterns of Goserelin 3.6 mg Once Every 4 Weeks and 10.8 mg Once Every 12 Weeks in Women With Breast Cancer: A Real-World Analysis of Patients in the United States

McCann KE, Kaklamani V, Osman N, Cannon J, Brent L, Lucia R, Li C, Duran N, Gupta S, Martin N. Treatment Patterns of Goserelin 3.6[...]

Neoadjuvant Chemotherapy Is Associated With Reduced Amputation Risk in Synovial Sarcoma of the Lower Extremity

Wahle CF, Newman-Hung NJ, Sakowitz S, Federman N, Singh AS, Bernthal NM, Benharash P, Wessel LE. Neoadjuvant Chemotherapy Is Associated With Reduced Amputation Risk in[...]

Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial

Lau G, Sangro B, Cheng AL, Kudo M, Kelley RK, Tak WY, Gasbarrini A, Reig M, Lim HY, Tougeron D, De Toni EN, Tam VC,[...]